GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.

葛兰素史克股份有限公司（LSE/NYSE:GSK）和CureVac N.V.（纳斯达克：CVAC）今天宣布，他们已将现有合作重组为新的许可协议，允许每家公司优先投资并专注于各自的mRNA开发活动。

Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in phase II and avian influenza in phase I clinical development. All candidates are based on CureVac’s proprietary second-generation mRNA backbone.

自2020年以来，GSK和CureVac一直在合作开发针对传染病的mRNA疫苗。通过这种合作，GSK和CureVac目前在II期和I期临床开发中都有季节性流感和新型冠状病毒肺炎的候选疫苗。。

Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines..

迄今为止，这些候选疫苗产生的数据很有希望，并证明它们有潜力成为同类最佳的新疫苗。。

Under the terms of the new agreement, GSK will assume full control of developing and manufacturing these candidate vaccines. GSK will have worldwide rights to commercialise the candidate vaccines. The agreement represents the latest step in GSK’s ongoing investment in vaccine platform technologies, matching the best platform to each pathogen to develop best-in-class vaccines.

。葛兰素史克将拥有全球范围内候选疫苗商业化的权利。该协议代表了葛兰素史克在疫苗平台技术方面持续投资的最新一步，将最佳平台与每种病原体相匹配，以开发一流的疫苗。

mRNA is an adaptable vaccine technology with demonstrated application in emerging and constantly changing viral pathogens due to its ability to support rapid strain change. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing..

mRNA是一种适应性强的疫苗技术，由于其支持快速菌株变化的能力，已被证明可用于新兴和不断变化的病毒病原体。GSK继续通过投资和合作伙伴关系开发和优化其mRNA能力，包括基于AI/ML的序列优化，纳米粒子设计和制造。。

CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range. The new agreement replaces all previous financial considerations from the prior collaboration agreement between GSK and CureVac.

CureVac将收到4亿欧元的预付款，另外还有10.5亿欧元的开发、监管和销售里程碑，以及从高单到低青少年的分层版税。新协议取代了葛兰素史克和CureVac之前合作协议中的所有财务考虑因素。

CureVac further retains exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration together with the freedom to independently develop and partner mRNA vaccines in any other infectious disease or other indication. CureVac’s ongoing patent litigation against Pfizer/BioNTech is unaffected by the new agreement..

CureVac进一步保留了先前合作中额外未公开和临床前验证的传染病靶标的专有权，以及在任何其他传染病或其他适应症中独立开发和合作mRNA疫苗的自由。CureVac针对辉瑞/生物技术公司正在进行的专利诉讼不受新协议的影响。。

Tony Wood, Chief Scientific Officer, GSK said: “We are excited about our flu/COVID-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care. With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace.”.

葛兰素史克首席科学官托尼·伍德（TonyWood）表示：“我们对我们的流感/新型冠状病毒肺炎（COVID-19）计划以及开发一流mRNA疫苗以改变护理标准的机会感到兴奋。通过这项新协议，我们将把葛兰素史克的能力、合作伙伴关系和知识产权应用于CureVac的技术，以快速提供这些有前景的疫苗。”。

Alexander Zehnder, Chief Executive Officer, CureVac said: “The collaboration with GSK has been instrumental in developing promising, late clinical-stage vaccine candidates, leveraging our proprietary mRNA platform. This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline.”.

CureVac首席执行官亚历山大·森德（AlexanderZehnder）表示：“与葛兰素史克（GSK）的合作有助于开发有前途的晚期临床候选疫苗，利用我们专有的mRNA平台。这项新的许可协议使我们处于强大的财务状况，并使我们能够专注于建立强大的研发渠道。”。

Completion of the new agreement remains subject to certain antitrust and regulatory approvals and customary closing conditions.

新协议的完成仍取决于某些反托拉斯和监管部门的批准以及惯例的交割条件。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性生物制药公司，旨在将科学、技术和人才团结起来，共同战胜疾病。更多信息请访问gsk.com。

About CureVac

关于CureVac

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need.

CureVac（纳斯达克股票代码：CVAC）是一家开创性的跨国生物技术公司，成立于2000年，旨在推进信使RNA（mRNA）技术在人类医学中的应用。在20多年的开发，优化和制造这种用于医疗目的的多功能生物分子的过程中，CureVac引入并改进了关键的基础技术，这些技术对于生产针对COVID-19的mRNA疫苗至关重要，目前正在为mRNA在主要未满足需求的新治疗领域的应用奠定基础。

CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins.

CureVac正在利用mRNA技术，结合先进的组学和计算工具，设计和开发现成的个性化癌症疫苗候选产品。。

Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com..

CureVac总部位于德国蒂宾根，在荷兰、比利时、瑞士和美国也有营业点。更多信息请访问www.CureVac.com。。